Related Experiment Video
Updated: Jun 27, 2026
Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors
Published on: March 1, 2020
[Serum galectin-9 in cervical cancer]
Mei-yan Liang1, Yan-ming Lu, Yao Zhang
1Department of Gynecology and Obstetrics, Shengjing Hospital, China Medical University, Shenyang 110004, China.
Objective:
To investigate the expression level of Galectin-9 (Gal-9) in the serum of cervical cancer patients and analyze the clinic significance of it.
Methods:
Collected sera from 29 patients with cervical cancer, 45 patients with cervical inter-epithelial lesion (CIN) and 26 normal females. Determination of Gal-9 was performed by ELISA, and in the group of patients with cervical cancer, these results were compared with the serum vascular endothelial growth factor (VEGF) and C-reactive protein (CRP). Then selecting four patients from the invasive cervical cancer group performed Gal-9 retrospective immuno-staining analysis.
Results:
Gal-9 concentration was 27.15 ng/L in the group of patients with cervical cancer that was significantly higher compared with the patients with CIN (21.20 ng/L) and the normal females (17.43 ng/L), and the Gal-9 concentration was significantly correlated with both VEGF and CRP in cervical cancer group. Two of these patients, who had a higher Gal-9 serum level, shown more intense staining and the other two patients, with lower serum level of Gal-9, had moderate immunostaining, suggesting that at least part of serum Gal-9 might be produced by cervical cancer tissue.
Conclusions:
Gal-9 might play a role in the progression and invasion of cervical cancer and warrants further study.
